

**Investigational HIV Medications
available at
The Institute for Family Health's
Sidney Hillman Family Practice on 16th Street in Manhattan**

An unprecedented surge in the development of antiretroviral medications has brought three important new drugs to the frontline of HIV treatment. These three new medications - one medication in an existing class and two in new classes of HIV medications have changed the paradigm of treatment. Full viral suppression for all patients is now the goal of HIV treatment.

The Institute is making available to medical practitioners and patients in the community, the new non-nucleoside drug etravavirine, formerly known as TMC-125 and the Merck integrase inhibitor raltegravir, formerly known as MK-0518. Both medications are available through expanded access programs for patients with virologic resistance to or intolerance of medications in the three major classes of antiretrovirals. The CCR5 co-receptor blocker maraviroc by Pfizer is also nearing availability through expanded access and the Institute expects to be offering it in late March or April.

The Institute is also participating in a study of therapeutic drug level monitoring at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences. Specimens on selected patients can be tested for levels of protease inhibitors and the non-nucleoside efavirenz (Sustiva).

HIV providers interested in having patients screened for eligibility for any of the above programs can contact Alice Welch, MPH, RPh at 212-924-7744, ext 320 or awelch@institute2000.org.